---
schema_version: "secwatch.filing_event.v1"
accession: "0001517022-23-000046"
form_type: "8-K"
ticker: "AKBA"
cik: "0001517022"
company_name: "Akebia Therapeutics, Inc."
filed_at: "2023-12-18T23:59:59+00:00"
generated_at: "2026-06-07T11:15:52.746518+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Akebia extends manufacturing supply agreement with Siegfried through 2026

## Summary
- Exercised option to extend Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA.
- Term extended from December 31, 2024 to December 31, 2026.
- Extension notice provided on December 14, 2023; all other terms unchanged.
- Supply continuity secured for active pharmaceutical ingredient manufacturing.

## SEC filing metadata
- accession: 0001517022-23-000046
- form_type: 8-K
- ticker: AKBA
- cik: 0001517022
- company_name: Akebia Therapeutics, Inc.
- filed_at: 2023-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000046/0001517022-23-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000046/akba-20231214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001517022-23-000046
- JSON: https://secwatch.observer/filing/0001517022-23-000046.json
- Plain text: https://secwatch.observer/filing/0001517022-23-000046.txt

## Key facts
- Material Agreements
  Akebia Therapeutics, Inc. amended Amendment No. 5 Master Manufacturing Services and Supply Agreement with Siegfried Evionnaz SA (effective 2023-02-28).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Siegfried Evionnaz SA
  - Effective: 2023-02-28
  source text: As previously disclosed, on February 28, 2023, Keryx Biopharmaceuticals, Inc., a wholly-owned subsidiary of Akebia Therapeutics, Inc. (the “Company”), and Siegfried Evionnaz SA (“Siegfried”) entered into Amendment No. 5 Master Manufacturing Services and Supply Agreement (the “Amendment”), which further amended the Master Manufacturing Services and Supply Agreement dated December 20, 2017 (as amended, the “Supply Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1517022/000151702223000046/0001517022-23-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.